3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
4
Withdrawn
1
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Dermatologic
1
Conditions
Leukemia, Myeloid, Acute
97
Myelodysplastic Syndromes
20
Leukemia, Myelomonocytic, Chronic
10
Recurrence
8
Leukemia
8
Neoplasm, Residual
6
Hematologic Neoplasms
6
Myeloproliferative Disorders
5
Lymphoma, T-Cell, Peripheral
5
Leukemia, Biphenotypic, Acute
5
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
4
Precursor Cell Lymphoblastic Leukemia-Lymphoma
3
Myelodysplastic-Myeloproliferative Diseases
3
Leukemia, Monocytic, Acute
3
Anemia, Refractory, with Excess of Blasts
3
Myeloid Malignancy
2
Multiple Myeloma
2
Lymphoma, T-Cell
2
Lymphoma
2
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
2
Hodgkin Disease
2
GATA2 Deficiency
2
Breast Neoplasms
2
Blastic Plasmacytoid Dendritic Cell Neoplasm
2
Uveal Melanoma
1
Squamous Cell Carcinoma of Head and Neck
1
Sarcoma, Myeloid
1
Pyloric Stenosis, Hypertrophic
1
Primary Myelofibrosis
1
Pathologic Complete Response
1
Interventions
pembrolizumab
54
Nivolumab
51
Ipilimumab
29
Cyclophosphamide
16
binimetinib
10
Specimen Handling
10
Magnetic Resonance Spectroscopy
10
fludarabine
9
Radiosurgery
9
relatlimab
8
encorafenib
8
Opdualag
8
Interleukin-2
8
Biopsy
8
aldesleukin
7
Blood Specimen Collection
7
atezolizumab
6
Immunotherapy
6
cemiplimab
5
CTLA-4 Antigen
5
Bevacizumab
5
trametinib
4
dabrafenib
4
Temozolomide
4
Paclitaxel
4
Immune Checkpoint Inhibitors
4
spartalizumab
3
fludarabine phosphate
3
Surgical Procedures, Operative
3
Metformin
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Melanoma
×
Azacitidine
×
Clear all
NCT04729543
2023-12-04
MC2TCR
Erasmus Medical Center
Phase 1/2
Recruiting
20 enrolled